Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PET

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431

Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962

Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum.

Fujiki, Y., Hubbard, A. L., Fowler, S., & Lazarow, P. B. (1982) · The Journal of Cell Biology · doi:10.1083/jcb.93.1.97 · Cited by 1,754

Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism

Cohen, S. I. A., Linse, S. S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218402110 · Cited by 1,450

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808

Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes

Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682

Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies

Polanco, J. C., Li, C., Bodea, L., Martínez‐Mármol, R., Meunier, F. A., & Götz, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 386

γ-Secretase in Alzheimer’s disease

Hur, J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 339

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease

Hadoux, X., Hui, F., Lim, J. K. H., Masters, C. L., Pébay, A., Chevalier, S., Ha, J. J., Loi, S. M., Fowler, C. J., Rowe, C. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12242-1 · Cited by 315

Aβ(1-42) tetramer and octamer structures reveal edge conductivity pores as a mechanism for membrane damage

Ciudad, S., Puig, E., Botzanowski, T., Meigooni, M., Arango, A. S., Do, J., Mayzel, M., Bayoumi, M., Chaignepain, S., Maglia, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16566-1 · Cited by 264

Quantification of amyloid PET for future clinical use: a state-of-the-art review

Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226

Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs

Alves, F. M., Kalinowski, P., & Ayton, S. (2023) · Neurology · doi:10.1212/wnl.0000000000207156 · Cited by 220

Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

Kim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 162

Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the 5XFAD Alzheimer's Disease Model

Shi, Q., Chang, C., Saliba, A., & Bhat, M. A. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2427-21.2022 · Cited by 139

Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies

Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129

Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain

Genoud, S., Roberts, B. R., Gunn, A. P., Halliday, G. M., Lewis, S. J. G., Ball, H. J., Hare, D. J., & Double, K. L. (2017) · Metallomics · doi:10.1039/c7mt00244k · Cited by 126

Cu and Zn interactions with Aβ peptides: consequence of coordination on aggregation and formation of neurotoxic soluble Aβ oligomers

Rana, M., & Sharma, A. K. (2018) · Metallomics · doi:10.1039/c8mt00203g · Cited by 116

Comparison of 18F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL® approaches: Validation against histopathology

Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93

Alzheimer's disease pathophysiology in the Retina

Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 107

Rapamycin and Alzheimer disease: a double-edged sword?

Carosi, J. M., & Sargeant, T. J. (2019) · Autophagy · doi:10.1080/15548627.2019.1615823 · Cited by 99

Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression

De, S., Whiten, D. R., Ruggeri, F. S., Hughes, C. D., Rodrigues, M., Sideris, D. I., Taylor, C. G., Aprile, F. A., Muyldermans, S., Knowles, T. P. J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0777-4 · Cited by 97

Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy

Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90

Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe

Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 87

Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation

Gomes, L. A., Uytterhoeven, V., Lopez-Sanmartin, D., Tomé, S. O., Tousseyn, T., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Verstreken, P., & Thal, D. R. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02251-6 · Cited by 77

Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age

Bergen, J. M. G. V., Li, X., Quevenco, F. C., Gietl, A. F., Treyer, V., Meyer, R., Buck, A., Kaufmann, P. A., Nitsch, R. M., van Zijl, P. C. M., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.03.021 · Cited by 77

Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy

Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 79

Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults

Chen, L., Soldan, A., Oishi, K., Faria, A. V., Zhu, Y., Albert, M., van Zijl, P. C. M., & Li, X. (2020) · Radiology · doi:10.1148/radiol.2020201603 · Cited by 76

Autophagy Modulation as a Treatment of Amyloid Diseases

Mputhia, Z., Hone, E., Tripathi, T., Sargeant, T. J., Martins, R. N., & Bharadwaj, P. (2019) · Molecules · doi:10.3390/molecules24183372 · Cited by 69

Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: Insights from studies in patient populations and animal models

Winsky‐Sommerer, R., de Oliveira, P., Loomis, S., Wafford, K. A., Dijk, D., & Gilmour, G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.027 · Cited by 69

Selective Secretase Targeting for Alzheimer’s Disease Therapy

Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66

Retinal Functional and Structural Changes in the 5xFAD Mouse Model of Alzheimer’s Disease

Lim, J. K. H., Li, Q.-X., He, Z., Vingrys, A. J., Chinnery, H. R., Mullen, J., Bui, B. V., & Nguyen, C. T. O. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00862 · Cited by 65

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression

Liebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68

Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease

Lobanova, E., Whiten, D. R., Ruggeri, F. S., Taylor, C. G., Kouli, A., Xia, Z., Emin, D., Zhang, Y. P., Lam, J. Y. L., Williams‐Gray, C. H., et al. (2021) · Brain · doi:10.1093/brain/awab306 · Cited by 65

The mTOR–lysosome axis at the centre of ageing

Carosi, J. M., Fourrier, C., Bensalem, J., & Sargeant, T. J. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13347 · Cited by 70

Secondary prevention of Alzheimer’s dementia: neuroimaging contributions

ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 65

The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression

Quartey, M. O., Nyarko, J. N. K., Maley, J. M., Barnes, J. R., Bolanos, M. A. C., Heistad, R. M., Knudsen, K. J., Pennington, P. R., Buttigieg, J. A., de Carvalho, C. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80164-w · Cited by 54

Physiological clearance of Aβ by spleen and splenectomy aggravates Alzheimer‐type pathogenesis

Yu, Z., Chen, D., Tan, C., Zeng, G., He, C.-Y., Wang, J., Bu, X., & Wang, Y. (2021) · Aging Cell · doi:10.1111/acel.13533 · Cited by 49

The emerging role of PET imaging in dementia

Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 52

Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease

Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., McLean, C., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2021) · Brain Communications · doi:10.1093/braincomms/fcab028 · Cited by 48

Neuronal spreading and plaque induction of intracellular Aβ and its disruption of Aβ homeostasis

Roos, T. T., Garcia, M. G., Martinsson, I., Mabrouk, R., Israelsson, B., Deierborg, T., Kobro‐Flatmoen, A., Tanila, H., & Gouras, G. K. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02345-9 · Cited by 48

β-amyloid: The known unknowns

Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45

Early Intervention in Alzheimer’s Disease: How Early is Early Enough?

Fan, D., & Wang, Y.-J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00429-x · Cited by 49

Endothelial leakiness elicited by amyloid protein aggregation

Li, Y., Ni, N., Lee, M., Wei, W., Andrikopoulos, N., Käkinen, A., Davis, T. P., Song, Y., Ding, F., Leong, D. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44814-1 · Cited by 52

Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease

Carosi, J. M., & Sargeant, T. J. (2023) · Autophagy · doi:10.1080/15548627.2023.2175569 · Cited by 41

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 44

The Validation of Multifactor Model of Plasma Aβ42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease

Jiao, F., Yi, F., Wang, Y., Zhang, S., Guo, Y., Du, W., Gao, Y., Ren, J., Zhang, H., Liu, L., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00212 · Cited by 40

Brain volume loss due to donanemab

Ayton, S. (2021) · European Journal of Neurology · doi:10.1111/ene.15007 · Cited by 33

What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies

Villemagne, V. L., Lopresti, B. J., Doré, V., Tudorascu, D., Ikonomović, M. D., Burnham, S. C., Minhas, D. S., Pascoal, T. A., Mason, N. S., Snitz, B. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245423 · Cited by 37

Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4

Quevenco, F. C., Bergen, J. M. G. V., Treyer, V., Studer, S. T., Kagerer, S. M., Meyer, R., Gietl, A. F., Kaufmann, P. A., Nitsch, R. M., Höck, C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00046 · Cited by 34

Plasma p‐tau181/Aβ 1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ 1‐42 and future cognitive decline

Fowler, C. J., Stoops, E., Rainey‐Smith, S. R., Vanmechelen, E., Vanbrabant, J., Dewit, N., Mauroo, K., Maruff, P. T., Rowe, C. C., Fripp, J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12375 · Cited by 36

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Pradier, L., Blanchard-Brégeon, V., Bohme, A., Debeir, T., Ménager, J., Benoit, P., Barnéoud, P., Taupin, V., Bertrand, P., Dugay, P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0447-y · Cited by 37

Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease

Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 36

Modulation of amyloid-β aggregation by metal complexes with a dual binding mode and their delivery across the blood–brain barrier using focused ultrasound

Chan, T. G., Rühl, C. L., Morse, S. V., Simon, M., Rakers, V., Watts, H. R., Aprile, F. A., Choi, J. J., & Vilar, R. (2021) · Chemical Science · doi:10.1039/d1sc02273c · Cited by 33

Longitudinal evaluation of the natural history of amyloid-β in plasma and brain

Burnham, S. C., Fandos, N., Fowler, C. J., Pérez‐Grijalba, V., Doré, V., Doecke, J. D., Shishegar, R., Cox, T. O., Fripp, J., Rowe, C. C., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa041 · Cited by 32

Oligopeptides Generated by Neprilysin Degradation of β-Amyloid Have the Highest Cu(II) Affinity in the Whole Aβ Family

Bossak‐Ahmad, K., Mital, M., Płonka, D., Drew, S. C., & Bal, W. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b03051 · Cited by 34

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum

Salvadó, G., Milà‐Alomà, M., Shekari, M., Minguillón, C., Fauria, K., Niñerola‐Baizán, A., Perissinotti, A., Kollmorgen, G., Buckley, C. J., Farrar, G., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12245 · Cited by 30

Citrullination of Amyloid-β Peptides in Alzheimer’s Disease

Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 30

Amylin in Alzheimer's disease: Pathological peptide or potential treatment?

Mietlicki‐Baase, E. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.016 · Cited by 30

Trans-Chalcone Plus Baicalein Synergistically Reduce Intracellular Amyloid Beta (Aβ42) and Protect from Aβ42 Induced Oxidative Damage in Yeast Models of Alzheimer’s Disease

Dhakal, S., Ramsland, P. A., Adhikari, B., & Macreadie, I. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179456 · Cited by 29

The β‐secretase (BACE) inhibitor NB‐360 in preclinical models: From amyloid‐β reduction to downstream disease‐relevant effects

Neumann, U., Machauer, R., & Shimshek, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14582 · Cited by 27

Impact of Acute and Chronic Amyloid-β Peptide Exposure on Gut Microbial Commensals in the Mouse

Guilherme, M. D. S., Todorov, H., Osterhof, C., Möllerke, A., Cub, K., Hankeln, T., Gerber, S., & Endres, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01008 · Cited by 30

Tumour necrosis factor induces increased production of extracellular amyloid-β- and α-synuclein-containing aggregates by human Alzheimer’s disease neurons

Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 28

Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease

Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 27

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01005-5 · Cited by 25

Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeutics

Paul, D., Chipurupalli, S., Justin, A., Raja, K., & Mohankumar, S. K. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106932 · Cited by 26

Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes

Valenza, M., Facchinetti, R., Menegoni, G., Steardo, L., & Scuderi, C. (2021) · Biomolecules · doi:10.3390/biom11040600 · Cited by 25

Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins

Oatman, S. R., Reddy, J. S., Quicksall, Z., Carrasquillo, M. M., Wang, X., Liu, C., Yamazaki, Y., Nguyen, T., Malphrus, K. G., Heckman, M. G., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00592-2 · Cited by 27

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

Geerts, H., Walker, M., Rose, R., Bergeler, S., van der Graaf, P. H., Schuck, E. L., Koyama, A., Yasuda, S., Hussein, Z., Reyderman, L., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12912 · Cited by 24

Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults

Schreiner, S. J., Kirchner, T., Narkhede, A., Wyss, M., Bergen, J. M. G. V., Steininger, S. C., Gietl, A. F., Leh, S. E., Treyer, V., Buck, A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.004 · Cited by 24

Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains

Mukherjee, S., Dubois, C., Perez, K. A., Varghese, S., Birchall, I. E., Leckey, M., Davydova, N., McLean, C., Nisbet, R. M., Roberts, B. R., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15713 · Cited by 22

Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer’s disease

Aljuhani, M., Ashraf, A., & Edison, P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae435 · Cited by 25

Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts

Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23

Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide

Molina-Fernández, R., Picón-Pagès, P., Barranco-Almohalla, A., Crepin, G., Herrera-Fernández, V., García-Elías, A., Fanlo-Ucar, H., Fernàndez‐Busquets, X., García‐Ojalvo, J., Oliva, B., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac243 · Cited by 23

The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

Tolar, M., Hey, J. A., Power, A., & Abushakra, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052727 · Cited by 23

An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure

Boopathi, S., Poma, A. B., & Garduño‐Juárez, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910798 · Cited by 20

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

Ramakrishnan, V., Friedrich, C. M., Witt, C. M., Sheehan, R., Pryor, M. M., Atwal, J. K., Wildsmith, K. R., Kudrycki, K., Lee, S., Mazer, N. A., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12876 · Cited by 19

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42

Zaretsky, D. V., Zaretskaia, M. V., Molkov, Y. I., & Initiative, A. D. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276933 · Cited by 23

Tyramine and Amyloid Beta 42: A Toxic Synergy

Dhakal, S., & Macreadie, I. G. (2020) · Biomedicines · doi:10.3390/biomedicines8060145 · Cited by 20

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease

Serra-Batiste, M., Tolchard, J. L., Giusti, F., Zoonens, M. A., & Carulla, N. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00038 · Cited by 16

CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer’s disease mouse model

Ennerfelt, H. E., Holliday, C., Shapiro, D. A., Zengeler, K. E., Bolte, A. C., Ulland, T. K., & Lukens, J. R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303760120 · Cited by 16

Endogenous Human Proteins Interfering with Amyloid Formation

Gharibyan, A. L., Jayaweera, S. W., Lehmann, M., Anan, I., & Olofsson, A. (2022) · Biomolecules · doi:10.3390/biom12030446 · Cited by 17

Mass spectrometric studies of the variety of beta‐amyloid proteoforms in Alzheimer's disease

Zakharova, N. V., Kononikhin, A. S., Indeykina, M. I., Bugrova, A. E., Strelnikova, P. A., Игоревич, П. С., Kozin, S. A., Popov, I. A., Mitkevich, V. A., Makarov, A. А., et al. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21775 · Cited by 16

Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer’s Disease for Research and Drug Development

Varshavskaya, K. B., Mitkevich, V. A., Makarov, A. А., & Barykin, E. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315036 · Cited by 17

Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity

Mastenbroek, S. E., Sala, A., García, D. V., Shekari, M., Salvadó, G., Lorenzini, L., Pieperhoff, L., Wink, A. M., Alves, I. L., Wolz, R., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209419 · Cited by 16

Increased cerebral blood volume in small arterial vessels is a correlate of amyloid-β–related cognitive decline

Hua, J., Lee, S. W., Blair, N. I. S., Wyss, M., Bergen, J. M. G. V., Schreiner, S. J., Kagerer, S. M., Leh, S. E., Gietl, A. F., Treyer, V., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.01.001 · Cited by 14

Enhanced ion mobility resolution of Abeta isomers from human brain using high-resolution demultiplexing software

Mukherjee, S., Fjeldsted, J. C., Masters, C. L., & Roberts, B. R. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04055-x · Cited by 14

A Systematic Bioinformatics Workflow With Meta-Analytics Identified Potential Pathogenic Factors of Alzheimer’s Disease

Yuen, S. C., Zhu, H., & Leung, S.-W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00209 · Cited by 16

Recent Research Progress in Fluorescent Probes for Detection of Amyloid-β In Vivo

Zhang, Z.-Y., Li, Z., Tang, Y.-H., Xu, L., Zhang, D., Qin, T., & Wang, Y. (2023) · Biosensors · doi:10.3390/bios13110990 · Cited by 13

The development of near-infrared hydrogen sulfide probes and its application in the past ten years

Li, Y., Nouman, N. M., Yin, C., & Huo, F. (2024) · Dyes and Pigments · doi:10.1016/j.dyepig.2024.112246 · Cited by 13

Apolipoprotein B gene expression and regulation in relation to Alzheimer’s disease pathophysiology

Aumont‐Rodrigue, G., Picard, C., Labonté, A., & Poirier, J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100667 · Cited by 14

Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age

Kagerer, S. M., Schroeder, C., Bergen, J. M. G. V., Schreiner, S. J., Meyer, R., Steininger, S. C., Vionnet, L., Gietl, A. F., Treyer, V., Buck, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.811146 · Cited by 14

Protein Self-Assembly at the Liquid–Surface Interface. Surface-Mediated Aggregation Catalysis

Lyubchenko, Y. L. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c09029 · Cited by 11

Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia

Martorana, A., Assogna, M., Lucia, V. D., Motta, C., Bonomi, C. G., Bernocchi, F., Donna, M. G. D., & Koch, G. (2021) · Minerva Medica · doi:10.23736/s0026-4806.21.07448-6 · Cited by 12

Upregulation of endocytic protein expression in the Alzheimer’s disease male human brain

Alsaqati, M., Thomas, R. S., & Kidd, E. J. (2023) · Aging Brain · doi:10.1016/j.nbas.2023.100084 · Cited by 10

Novel Amylin Analogues Reduce Amyloid-β Cross-Seeding Aggregation and Neurotoxicity

Dharmaraj, G. L., Arigo, F. D., Young, K. A., Martins, R. N., Mancera, R. L., & Bharadwaj, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215339 · Cited by 9

Exploring tau protein and amyloid-beta propagation: A sensitivity analysis of mathematical models based on biological data

Corti, M. (2024) · Brain Multiphysics · doi:10.1016/j.brain.2024.100098 · Cited by 8

Interactions between daily sleep-wake rhythms, γ-secretase, and amyloid-β peptide pathology point to complex underlying relationships

Turton, S. M., Padgett, S., Jessup, M. T., Johnson, C. E., Buzinova, V. A., Barth, S. E., Köhler, K., Spearman, H. M., Macheda, T., Manauis, E. C., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167840 · Cited by 7

Insights into Membrane Damage by α-Helical and β-Sheet Peptides

Rangubpit, W., Distaffen, H. E., Nilsson, B. L., & Dias, C. L. (2025) · Biomolecules · doi:10.3390/biom15070973 · Cited by 8

Modifying Dietary Protein Impacts mTOR Signaling and Brain Deposition of Amyloid β in a Knock-In Mouse Model of Alzheimer Disease

Bensalem, J., Hein, L. K., Hassiotis, S., Trim, P. J., Proud, C. G., Heilbronn, L. K., & Sargeant, T. J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.02.035 · Cited by 8

Polyphenol-Peptide Interactions in Mitigation of Alzheimer’s Disease: Role of Biosurface-Induced Aggregation

Gaudreault, R., Hervé, V., van de Ven, T. G. M., Mousseau, N., & Ramassamy, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201549 · Cited by 8

Early divergent modulation of NLRP2′s and NLRP3′s inflammasome sensors vs. AIM2′s one by signals from Aβ·Calcium-sensing receptor complexes in human astrocytes

Chiarini, A., Armato, U., Gui, L., Yin, M., Chang, S., & Prà, I. D. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149283 · Cited by 7

Phytochemical Compounds Loaded to Nanocarriers as Potential Therapeutic Substances for Alzheimer’s Disease-Could They be Effective?

Polat, D. Ç., Karadağ, A. E., Köprülü, R. E. P., Karantas, I. D., Mutlu, G., Çağlar, E. Ş., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220411104128 · Cited by 7

Unveiling the Therapeutic Potential of Kelulut (Stingless Bee) Honey in Alzheimer’s Disease: Findings from a Rat Model Study

Shaikh, A., Ahmad, F., Teoh, S. L., Kumar, J., & Yahaya, M. F. (2024) · Antioxidants · doi:10.3390/antiox13080926 · Cited by 10

Distinct Pools of ␤-Amyloid in Alzheimer Disease–Affected Brain

Steinerman, J. R., Irizarry, M. C., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B. T., & Stern, Y. (2022) · doi:10.7916/j0pe-r896

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Guo, T. (2018) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)

Amyloid (B-protein (Aß) Accumulation in the Putamen and Mammillary Body during Aging and in Alzheimer Disease

Nakabayash, J., Yoshimura, M., Morishima‐Kawashima, M., Funato, H., Miyakawa, T., Yamazaki, T., & Ihara, Y. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199804000-00007 · Cited by 26

Distinct Pools of β-Amyloid in Alzheimer Disease-Affected Brain: A Clinicopathologic Study

Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B. T., & Stern, Y. (2008) · JAMA Neurology · doi:10.7916/d8ht2p4s

Distribution of isomerized and racemized amyloid β isoforms in sporadic Alzheimer’s disease using ion‐mobility mass spectrometry

Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.039256